You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Antibody therapies for lymphoma in children
|
|---|---|
| Published in |
Cochrane database of systematic reviews, January 2016
|
| DOI | 10.1002/14651858.cd011181.pub2 |
| Pubmed ID | |
| Authors |
Verena de Zwart, Samantha C Gouw, Friederike AG Meyer‐Wentrup |
| Abstract |
Lymphomas are the third most common malignancy in childhood. Cure rates are high but have reached a plateau. Therefore new treatment modalities should be developed. Antibody therapy is a successful new treatment option in adult lymphoma. However, none of the therapeutic antibodies available for adults with cancer have been approved for treatment of paediatric lymphoma. To assess the efficacy of antibody therapy for childhood lymphoma in terms of survival, response and relapse rates, compared with therapy not including antibody treatment. To assess quality of life and the occurrence of adverse effects caused by antibody therapy treatment in children compared with therapy not including antibody treatment. We searched the Cochrane Central Register of Controlled Trials (CENTRAL, 2014, Issue 10), MEDLINE in PubMed (from 1945 to October 2014), EMBASE in EMBASE.com (from 1980 to October 2014) and reference lists of relevant articles. Furthermore, we searched conference proceedings abstracts of SIOP, ASCO and ASH for studies from 2009 to 2013), and the World Health Organization (WHO) ICTRP portal and ClinicalTrials.gov for ongoing trials. Randomised controlled trials and controlled clinical trials comparing conventional therapy with antibody therapy in children with lymphoma. Two authors independently performed the study selection. We found no studies meeting the inclusion criteria of the review. At this moment, it is not possible to draw evidence-based conclusions regarding clinical practice. Phase I and II studies show a positive effect of using antibody therapy in childhood lymphoma. Further research is needed to evaluate and implement antibody therapy for paediatric lymphoma. |
X Demographics
The data shown below were collected from the profiles of 12 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Saudi Arabia | 2 | 17% |
| United Kingdom | 2 | 17% |
| Estonia | 1 | 8% |
| Mexico | 1 | 8% |
| Spain | 1 | 8% |
| Germany | 1 | 8% |
| Netherlands | 1 | 8% |
| United States | 1 | 8% |
| Unknown | 2 | 17% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 58% |
| Practitioners (doctors, other healthcare professionals) | 4 | 33% |
| Scientists | 1 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 122 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 122 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 18 | 15% |
| Student > Bachelor | 15 | 12% |
| Researcher | 11 | 9% |
| Other | 10 | 8% |
| Student > Ph. D. Student | 9 | 7% |
| Other | 13 | 11% |
| Unknown | 46 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 32 | 26% |
| Nursing and Health Professions | 16 | 13% |
| Biochemistry, Genetics and Molecular Biology | 5 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 2% |
| Psychology | 3 | 2% |
| Other | 12 | 10% |
| Unknown | 51 | 42% |
Attention Score in Context
This research output has an Altmetric Attention Score of 22. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 December 2019.
All research outputs
#1,715,335
of 25,809,966 outputs
Outputs from Cochrane database of systematic reviews
#3,642
of 13,159 outputs
Outputs of similar age
#29,235
of 406,189 outputs
Outputs of similar age from Cochrane database of systematic reviews
#83
of 255 outputs
Altmetric has tracked 25,809,966 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,159 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.8. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 406,189 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 255 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.